Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Jonathan Ticku

Hematology Oncology | Hematology | Oncology
Mayo Clinic Health System-Southwest Wisconsin Region Inc
800 E Blackhawk Ave, 
Prairie Du Chien, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
Mayo Clinic Health System-Southwest Wisconsin Region Inc
800 E Blackhawk Ave, 
Prairie Du Chien, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Ticku is a Hematologist Oncology specialist and a Hematologist in Prairie Du Chien, Wisconsin. Dr. Ticku is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Colorectal Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Ticku is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic Health System Chippewa Valley
Mayo Clinic Health System-Franciscan Medical Center Inc
Mayo Clinic Health System Eau Claire Hospital
Mayo Clinic Hlth Systm Franciscan Hlthcare Sparta
Mayo Clinic Health System-Northland
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 E Blackhawk Ave, Prairie Du Chien, WI 53821
Other Locations
MAYO CLINIC HEALTH SYSTEM-NORTHWEST WISCONSIN REGION INC
1400 Bellinger St, Eau Claire, WI 54703
MAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION INC
800 W Ave S, La Crosse, WI 54601

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Enrollment Status: Recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug, Biological, Other, Dietary supplement
Study Drugs: Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Oxaliplatin, Rituximab
Study Phase: Phase 2
Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial
Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Palmidrol
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 4 Less Clinical Trials

4 Total Publications

Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 30, 2023
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mark E. Hermann
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mark E. Hermann
Hematology Oncology | Oncology

Dubuque Internal Medicine PC

350 N Grandview Ave, Suite 2300, 
Dubuque, IA 
 (44.7 miles away)
563-589-4003
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Hermann is a Hematologist Oncology specialist and an Oncologist in Dubuque, Iowa. Dr. Hermann is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Primary Lymphoma of the Brain, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes. Dr. Hermann is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David Marinier
Hematology | Oncology

Gundersen Clinic Ltd

123 Se 5th Ave, 
Spring Grove, MN 
 (42.9 miles away)
507-498-3302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Marinier is a Hematologist and an Oncologist in Spring Grove, Minnesota. Dr. Marinier is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, and Lynch Syndrome.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Anna C. Jones
Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Anna C. Jones
Hematology | Oncology

Mayo Clinic Health System-Southwest Wisconsin Region Inc

800 W Ave S, 
La Crosse, WI 
 (52.1 miles away)
608-785-0940
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anna Jones is a Hematologist and an Oncologist in La Crosse, Wisconsin. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Adult Soft Tissue Sarcoma, Colorectal Cancer, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer. Dr. Jones is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ticku's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 45 Advanced Conditions
    View All 140 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile